Kiora Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 12
- Market Cap
- -
- Website
- http://www.kiorapharma.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Kiora Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06825702
- Locations
- 🇦🇺
Sydney Eye Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Centre for Eye Research Australia, East Melbourne, Victoria, Australia
A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
- Conditions
- Retinitis Pigmentosa
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Kiora Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06628947
- Locations
- 🇦🇺
Save Sight Institute, Sydney, New South Wales, Australia
🇦🇺Queensland Eye Institute, Woolloongabba, Queensland, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Kiora Pharmaceuticals, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT05629364
- Locations
- 🇦🇺
Ophthalmic Trials Australia, Teneriffe, Queensland, Australia
A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- Drug: KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Kiora Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05436288
- Locations
- 🇲🇽
Instituto de Oftalmología Fundación Conde de Valenciana, Mexico City, Chimalpopoca 14 Colonia Obrera, Mexico
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Kiora Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05282953
- Locations
- 🇦🇺
Royal Adeliade Hospital, Adelaide, South Australia, Australia
🇦🇺Harley Eye Clinic, North Adelaide, South Australia, Australia